Endometrial cancer data on Genmab’s Elahere rival beat forecast, fueling push into phase 3
Genmab has shared the first data on rinatabart sesutecan in advanced endometrial cancer. The biotech reported a 50% unconfirmed response rate, beating the expectations of William Blair analysts to boost confidence in the program ahead of its move into phase 3.
Genmab has shared the first data on rinatabart sesutecan in advanced endometrial cancer. The biotech reported a 50% unconfirmed response rate, beating the expectations of William Blair analysts to boost confidence in the program ahead of its move into phase 3.
